Evaluation More than Skin Deep: Examining the Full Impact of Tardive Dyskinesia - Self-Paced Activity Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Timothy Balisky MSN, PMHNP-BC 5 4 3 2 1 Desiree Matthews, PMHNP 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Describe the pathophysiology, consequences, and long-term prognosis of TD, including negative impacts on physical, cognitive, and psychosocial functioning 5 4 3 2 1 Implement optimal assessment strategies for the detection and evaluation of TD 5 4 3 2 1 Describe the mechanisms of action and differences in pharmacology associated with VMAT-2 inhibitors approved for TD 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with Tardive Dyskinesia on a weekly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage Tardive Dyskinesia. Excellent Very Good Good Fair Poor Based on my participation in this activity, I anticipate I will more often: (select all that apply) Routinely screen for TD in appropriate patients Evaluate symptoms of TD with a structured instrument at a minimum of every 6 months Involve the entire treatment team, including patients and care partners, to recognize/report involuntary movements Assess the impact of TD on patients’ physical, psychological, and social well-being Prescribe VMAT2 inhibitors for patients with symptoms of TD, depending on patient factors and preference, associated impairment, effect on psychosocial functioning, etc. Avoid prescribing benztropine or other anticholinergic medications unnecessarily Tailor treatment to address individual patient needs Other (please specify): Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max
